Skip to Content

Join the 'Cryopyrin-Associated Periodic Syndromes' group to help and get support from people like you.

Cryopyrin-Associated Periodic Syndromes News

Related terms: CAPS

FDA approves Kineret for the treatment of NOMID

Posted 8 Jan 2013 by

Sobi (STO: SOBI) today announced that the US Food and Drug Administration (FDA) has approved Kineret® (anakinra) for the treatment of children and adults with neonatal-onset multisystem inflammatory disease (NOMID). Kineret is the first and only FDA-approved therapy for NOMID, the most severe form of cryopyrin associated periodic syndromes (CAPS). This is the first approval allowing the use of Kineret in children. Kineret was approved for NOMID under an Orphan Drug designation. A priority review was granted by the FDA based on the product's potential to provide a significant advance in therapy for the NOMID patient population where no adequate therapy exists. Sobi will provide a prefilled syringe with a graduated label to allow flexible dosing in children. Kineret has been approved for the reduction of signs and symptoms of Rheumatoid Arthritis (RA) in adults since 2001. CAPS is, in its ... Read more

Related support groups: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Kineret, Anakinra

Ask a Question

Further Information

Related Condition Support Groups

Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Periodic Fever Syndrome

Related Drug Support Groups

Kineret, Ilaris, rilonacept, Arcalyst, anakinra, canakinumab